In conclusion, increased hepatic SHP nuclear localization is associated with key pathological characteristics, including hepatic inflammation, steatosis, and metabolic syndrome, in patients with MASH; however, it does not emerge as a traditionally recognized suppressive factor that is negatively correlated with BA synthesis. Here, NR0B2 is linked to metabolic syndrome.